Asthma and Chronic Obstructive Pulmonary Disease (Copd) – Differences and Similarities
Vesna Cukic, Vladimir Lovre, Dejan Dragisic, Aida Ustamujic
Mat Soc Med. 2012; 24(2): 100-105
Bronchial asthma and COPD (chronic obstructive pulmonary disease) are obstructive pulmonary diseases that affected millions of people all over the world. Asthma is a serious global health problem with an estimated 300 million affected individuals. COPD is one of the major causes of chronic morbidity and mortality and one of the major public health problems worldwide. COPD is the fourth leading cause of death in the world and further increases in its prevalence and mortality can be predicted. Although asthma and COPD have many similarities, they also have many differences. They are two different diseases with differences in etiology, symptoms, type of airway inflammation, inflammatory cells, mediators, consequences of inflammation, response to therapy, course. Some similarities in airway inflammation in severe asthma and COPD and good response to combined therapy in both of these diseases suggest that they have some similar patophysiologic characteristics. The aim of this article is to show similarities and differences between these two diseases. Today asthma and COPD are not fully curable, not identified enough and not treated enough and the therapy is still developing. But in future better understanding of pathology, adequate identifying and treatment, may be and new drugs, will provide a much better quality of life, reduced morbidity and mortality of these patients.
1. GINA (Global Initiative for Asthma) – global strategy for asthma management and prevention, revised 2006. Http//www.ginasthma.org.: 1-92.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summaryof the GINA Dissemination Committee report. Allergy. 2004; 59(5): 469-478.
3. Beasley R. The Global Burden of Asthma Report, Global Initiative for Asthma (GINA). Available from http://www.ginasthma.org 2004.
4. Holgate ST. Genetic and environmental interaction in allergy and asthma. J Allergy Clin Immunol. 1999; 104(6):1139-1146.
5. Holloway JW, Beghe B, Holgate ST.The genetic basis of atopic asthma. Clin Exp Allergy. 1999; 29(8):1023-1032.
6. Wiesch DG, Meyers DA, Bleecker ER. Genetics of asthma. J Allergy Clin Immunol. 1999; 104(5):895-901.
7. Robinson DS. The role of the mast cell in asthma: induction of airway hyperresponsiviness by interaction with smooth muscle? J Allergy Clin Immunol. 2004; 114 (1): 58-65.
8. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends Immunol. 2004; 25(9):477-482.
9. Larche M, Robinson DS, Kay A B. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol. 2003; 111(3): 450-463.
10. Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, Kronenberg M, et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med. 2006; 354(11): 1117-1129.
11. Kuipers H, Lambrecht BN. The interplay of dendritic cells, Th2 cells and regulatory T cells in asthma. Curr Opin Immunol. 2004; 16(6): 702-708.
12. Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol. 2004; 31(1): 3-7.
13. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy. 2003; 33(12):1622-1628.
14. Chung KF. Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation? Eur Respir J 2000; 15(5): 961-968.
15. Groneberg DA, Quarcoo D, Frossard N, Fischer A. Neurogenic mechanisms in bronchial inflammatory diseases. Allergy.2004; 59(11): 1139-1152.
16. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev. 1998; 5 0(4): 515-596.
17. Miller AL, Lukacs NW. Chemokine receptors: understanding their role in asthmatic disease. Immunol Allergy Clin North Am. 2004; 24(4): 667-683.
18. Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Med Rev. 2001; 52: 1-14
19. Barnes PJ. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol. 2002; 42: 81-98.
20. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev. 2004; 84(3): 731-765.
21. Smith AD, Taylor DR. Is exhaled nitric oxide measurement a useful clinical test in asthma? Curr Opin Allergy Clin Immunol. 2005; 5(1): 49-56.
22. James A. Airway remodeling in asthma. Curr Opin Pulm Med. 2005; 11(1): 1-6.
23. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, et al. Airway remodeling in asthma. Chest. 2003; 123(3 Suppl): 417S-422S.
24. GOLD (Global Initiative for Chronic Obstructive Lung Disease) – global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, revised 2006. Http//www.goldcopd.org.: 1-100
25. World Health Report. Geneva: World Health Organization. Available from URL: http://www.who.int/whr/2000/en/statistics.htm; 2000.
26. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006; 27(2): 397-412.
27. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005; 128(4): 2099-2107.
28. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2(4): 367-370.
29. Van Weel C, Schellevis FG. Comorbidity and guidelines: conflicting interests. Lancet. 2006; 367(9510): 550-551.
30. Eisner MD, Balmes J, Katz BP, Trupin L, Yelin E, Blanc P. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health Perspect. 2005; 4: 7-15.
31. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003; 22(4): 672-688.
32. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364(9435): 709-721.
33. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163(6): 1304-1309.
34. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(26):2645-2653.
35. Cosio MG, Majo J. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002; 121(5 Suppl):160S-165S.
36. Barnes PJ. Macrophages as orchestrators of COPD. J COPD. 2004; 1: 59-70.
37. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004; 56(4): 515-548.
38. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy. 2005; 60(1): 23-29.
39. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J. 2004; 24(1): 122-128
40. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests.Eur Respir J. 2005; 26(5): 948-968.
41. Standardization of Spirometry, 1994. Update. American ThoracicSociety. Am J Respir Crit Care Med. 1995; 152(3): 1107-1136.
42. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993; 16: 1-100.
43. Barnes PJ. Efficacy of inhaled corticosteroids in asthma.J Allergy Clin Immunol. 1998; 102(4 Pt 1): 531-538.
44. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM,Drazen JM, et al. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am J Respir Crit Care Med. 1996; 153(6 Pt 1): 1739-1748
45. Newman SP. Inhaler treatment options in COPD. Eur Respir Rev. 2005; 14(96): 102-108.
46. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute.National Institutes of Health, 1997.
47. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Jr., Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroidsin patients with persistent asthma: a randomized controlled trial. JAMA. 2001; 285(20): 2583-2593.
48. Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database Syst Rev. 2005(2): CD001002.
49. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA.Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003; 58(8): 654-658.
50. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibilityt esting in chronic obstructive pulmonary disease. Thorax. 2003; 58(8): 659-664.
51. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320(7245): 1297-1303.
52. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax. 2005; 60(4): 301-304.
53. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis. 1987;1 35(5): 1069-1074.
54. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2003; 361(9356): 449-456.